What is MicroPort CardioFlow Medtech Operating Cash Flow per Share?
MicroPort CardioFlow Medtech's operating cash flow per share for the
six
months ended in Dec. 2023 was HK$-0.04.
MicroPort CardioFlow Medtech's operating cash flow per share for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-0.10.
During the past 3 years, the average Operating Cash Flow per Share Growth Rate was -20.40% per year.
During the past 5 years, the average Operating Cash Flow per Share Growth Rate was 37.10% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.
The historical rank and industry rank for MicroPort CardioFlow Medtech's Operating Cash Flow per Share or its related term are showing as below:
HKSE:02160'
s 3-Year OCF Growth Rate Range Over the Past 10 Years
Min: -35.7 Med: -20.4 Max: 91.2
Current: -20.4
During the past 6 years, MicroPort CardioFlow Medtech's highest 3-Year average Operating Cash Flow per Share Growth Rate was 91.20% per year. The lowest was -35.70% per year. And the median was -20.40% per year.
HKSE:02160's 3-Year OCF Growth Rate is ranked worse than 76.74% of 688
companies
in the Medical Devices & Instruments industry
Industry Median: 2.85
vs HKSE:02160: -20.40
MicroPort CardioFlow Medtech Operating Cash Flow per Share Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
MicroPort CardioFlow Medtech Operating Cash Flow per Share Chart
Competitive Comparison of MicroPort CardioFlow Medtech's Operating Cash Flow per Share
For the Medical Devices subindustry, MicroPort CardioFlow Medtech's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MicroPort CardioFlow Medtech's Price-to-Operating-Cash-Flow Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, MicroPort CardioFlow Medtech's Price-to-Operating-Cash-Flow distribution charts can be found below:
* The bar in red indicates where MicroPort CardioFlow Medtech's Price-to-Operating-Cash-Flow falls into.
MicroPort CardioFlow Medtech Operating Cash Flow per Share Calculation
Operating Cash Flow per Share is the amount of Cash Flow from Operations per outstanding share of the company's stock.
MicroPort CardioFlow Medtech's Operating Cash Flow per Share for the fiscal year that ended in Dec. 2023 is calculated as
Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-0.10
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MicroPort CardioFlow Medtech Operating Cash Flow per Share Related Terms
Thank you for viewing the detailed overview of MicroPort CardioFlow Medtech's Operating Cash Flow per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
MicroPort CardioFlow Medtech (HKSE:02160) Business Description
MicroPort CardioFlow Medtech Corp is a medical device company in China focusing on the research, development, and commercialization of transcatheter and surgical solutions for valvular heart diseases. The company's product portfolio consists of three products VitaFlow, VitaFlow Liberty, and Alwide Plus, and various TAVI products, TMV products, TTV products, surgical valve products, and procedural accessories. Geographically, it derives a majority of its revenue from China.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HKSE:02160 has been successfully added to your 